Previous Close | 1.17 |
1-Year Change | -84.19% |
6-Months Change | -1.68% |
3-Months Change | 3.54% |
Moving Avg (50d) | 1.2404 |
Moving Avg (200d) | 1.181 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 82.9M |
Beta (3-Years) | 1.05 |
Revenue Growth (ttm) | -8.8% |
Net Profit Margin (ttm) | -534.83% |
Return On Assets (ttm) | -52.5% |
EPS (ttm) | -1.66 |
PE Ratio (ttm) | -0.7 |
Dividend Yield | 0% |
Asset Description: | Aclaris Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-08-22 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
1.193 | 1.228 | 1.252 | 1.287 | 1.345 | 1.404 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |